Results of a real-world study on vortioxetine in patients with major depressive disorder in South East Asia (REVIDA)

References

• American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th edn. Arlington: American Psychiatric Association, 2013
   Google Scholar
• Woo JM, Kim W, Hwang TY, et al. Impact of depression on work productivity and its improvement after outpatient treatment with antidepressants. Value Health 2011;14:475-82
   PubMed Web of Science ®Google Scholar
• Harvey SB, Glozier N, Henderson M, et al. Depression and work performance: an ecological study using web-based screening. Occup Med (Oxford, England) 2011;61:209-11
   PubMed Web of Science ®Google Scholar
• Rizvi SJ, Grima E, Tan M, et al. Treatment-resistant depression in primary care across Canada. Can J Psychiatry 2014;59:349-57
   PubMed Web of Science ®Google Scholar
• Seemuller F, Meier S, Obermeier M, et al. Three-year long-term outcome of 458 naturalistically treated inpatients with major depressive episode: severe relapse rates and risk factors. Eur Arch Psychiatry Clin Neurosci 2014;264:567-75
   PubMed Web of Science ®Google Scholar
• Novick D, Hong J, Montgomery W, et al. Predictors of remission in the treatment of major depressive disorder: real-world evidence from a 6-month prospective observational study. Neuropsychiatr Dis Treat 2015;11:197-205
   PubMed Web of Science ®Google Scholar
• Saragoussi D, Touya M, Haro JM, et al. Factors associated with failure to achieve remission and with relapse after remission in patients with major depressive disorder in the PERFORM study. Neuropsychiatr Dis Treat 2017;13:2151-65
   PubMed Web of Science ®Google Scholar
• Ashton AK, Jamerson BD, W LW, et al. Antidepressant-related adverse effects impacting treatment compliance: results of a patient survey. Curr Therapeut Res Clin Exp 2005;66:96-106
   PubMed Web of Science ®Google Scholar
• Morehouse R, Macqueen G, Kennedy SH. Barriers to achieving treatment goals: a focus on sleep disturbance and sexual dysfunction. J Affect Disord 2011;132(Suppl 1):S14-S20
   PubMed Web of Science ®Google Scholar
• Bang-Andersen B, Ruhland T, Jorgensen M, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem 2011;54:3206-21
   PubMed Web of Science ®Google Scholar
• Richelson E. Multi-modality: a new approach for the treatment of major depressive disorder. Int J Neuropsychopharmacol 2013;16:1433-42
   PubMed Web of Science ®Google Scholar
• Westrich LPA, Zhong H, Nielsen SM, et al. In vitro and in vivo effects of the multimodal antidepressant vortioxetine (Lu AA21004) at human and rat targets. Int J Psychiatry Clin Pract 2012;16(Suppl 1):47
   Google Scholar
• Pehrson AL, Leiser SC, Gulinello M, et al. Treatment of cognitive dysfunction in major depressive disorder – a review of the preclinical evidence for efficacy of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors and the multimodal-acting antidepressant vortioxetine. Eur J Pharmacol 2015;753:19-31
   PubMed Web of Science ®Google Scholar
• Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Therapeut 2015;145:43-57
   PubMed Web of Science ®Google Scholar
• Alvarez E, Perez V, Dragheim M, et al. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychophar-macol 2012;15:589-600
   PubMed Web of Science ®Google Scholar
• Boulenger JP, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol 2014;29:138-49
   PubMed Web of Science ®Google Scholar
• Henigsberg N, Mahableshwarkar AR, Jacobsen P, et al. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry 2012;73:953-9
   PubMed Web of Science ®Google Scholar
• Jacobsen PL, Mahableshwarkar AR, Serenko M, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. J Clin Psychiatry 2015;76:575-82
   PubMed Web of Science ®Google Scholar
• Mahableshwarkar AR, Jacobsen PL, Chen Y, et al. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology 2015;232:2061-70
   PubMed Web of Science ®Google Scholar
• Gibb A, Deeks ED. Vortioxetine: first global approval. Drugs 2014;74:135-45
   PubMed Web of Science ®Google Scholar
• Mahableshwarkar AR, Zajecka J, Jacobson W, et al. A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology 2015;40:2025-37
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Florea I, Tonnoir B, et al. Efficacy of vortioxetine on cognitive functioning in working patients with major depressive disorder. J Clin Psychiatry 2017;78:115-21
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Harrison J, Loft H, et al. The effects of vortioxetine on cognitive function in patients with major depressive disorder: a meta-analysis of three randomized controlled trials. Int J Neuropsychopharmacol 2016;19(10):1-9
   Web of Science ®Google Scholar
• McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol 2014;17:1557-67
   PubMed Web of Science ®Google Scholar
• Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol 2012;27:215-23
   PubMed Web of Science ®Google Scholar
• Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001;16:606-13
   PubMed Web of Science ®Google Scholar
• Fehnel SE, Forsyth BH, DiBenedetti DB, et al. Patient-centered assessment of cognitive symptoms of depression. CNS Spectrums 2016;21:43-52
   PubMed Web of Science ®Google Scholar
• Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics 1993;4:353-65
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Hansen T, Florea I. Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. Curr Med Res Opin 2012;28:1717-24
   PubMed Web of Science ®Google Scholar
• Alam MY, Jacobsen PL, Chen Y, et al. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Int Clin Psychopharmacol 2014;29:36-44
   PubMed Web of Science ®Google Scholar
• Huynh NN, McIntyre RS. What are the implications of the STAR*D trial for primary care? A review and synthesis. Primary Care Companion to J Clin Psychiatry 2008;10:91-6
   PubMedGoogle Scholar
• Meeker AS, Herink MC, Haxby DG, et al. The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis. Syst Rev 2015;4:21
   PubMed Web of Science ®Google Scholar
• Sung SC, Low CC, Fung DS, et al. Screening for major and minor depression in a multiethnic sample of Asian primary care patients: a comparison of the nine-item Patient Health Questionnaire (PHQ-9) and the 16-item Quick Inventory of Depressive Symptomatology – Self-Report (QIDS-SR16). Asia-Pacific Psychiatry 2013;5:249-58
   PubMed Web of Science ®Google Scholar
• Lotrakul M, Sumrithe S, Saipanish R. Reliability and validity of the Thai version of the PHQ-9. BMC Psychiatry 2008;8:46
   PubMed Web of Science ®Google Scholar
• Sherina MS, Arroll B, Goodyear-Smith F. Criterion validity of the PHQ-9 (Malay version) in a primary care clinic in Malaysia. Med J Malaysia 2012;67:309-15
   PubMedGoogle Scholar
• Hawley CJ, Gale TM, Smith PS, et al. Equations for converting scores between depression scales (MADRS, SRS, PHQ-9 and BDI-II): good statistical, but weak idiographic, validity. Hum Psychopharmacol 2013;28:544-51
   PubMed Web of Science ®Google Scholar
• Al-Sukhni M, Maruschak NA, McIntyre RS. Vortioxetine: a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder. Expert Opin Drug Saf 2015;14:1291-304
   PubMed Web of Science ®Google Scholar
• McIntyre RS, ed. Cognitive Impairment in Major Depressive Disorder: Clinical Relevance, Biological Substrates, and Treatment Opportunities. Cambridge: Cambridge University Press, 2016
   Google Scholar
• Lam R, Saragoussi D, Danchenko N, et al. Psychometric validation of perceived deficits questionnaire – depression (PDQ-D) in patients with major depressive disorder (MDD). Value Health 2013;16:A330
   Web of Science ®Google Scholar
• Beck A, Crain LA, Solberg LI, et al. The effect of depression treatment on work productivity. Am J Manag Care 2014;20:e294-301
   PubMed Web of Science ®Google Scholar
• Sansone RA, Sansone LA. Antidepressant adherence: are patients taking their medications? Innovat Clin Neurosci 2012;9:41-6
   Google Scholar